Key Highlights

  • Verici Dx PLC — LSE:VRCI — gained 11.11% on 28 September 2026.
  • The company is developing precision diagnostics for organ-transplant patients, with a particular focus on kidney transplantation.
  • A major near-term catalyst is the planned Q4 2026 launch of TranscripTx, a genetic test designed specifically for transplant patients.
  • Tutivia testing volumes increased strongly during the first quarter of 2026, supporting the company's commercialisation strategy.
  • Verici Dx has now secured laboratory certification covering all 50 US states and Washington, D.C.
  • The company has also expanded its laboratory capabilities through an Olink certified service-provider agreement.
  • Investors are watching whether increasing test adoption can translate into sustained commercial Revenue growth.

Why Is Verici Dx (LSE:VRCI) in Focus Today?

Verici Dx has attracted renewed investor attention after LSE:VRCI rose 11.11% on 28 September 2026.

The company is positioned at the intersection of healthcare diagnostics, artificial intelligence and transplant medicine. Its technology uses RNA and multiomic data to identify biological signals that may help clinicians understand transplant-patient risk and response.

The latest focus is increasingly shifting toward commercialisation. Verici is expanding the availability of its existing Tutivia test while preparing to launch its new TranscripTx genetic test during Q4 2026.

This creates multiple potential catalysts for the company during the remainder of the year.

Why Did LSE:VRCI Rise 11.11% on 28 September 2026?

The 11.11% increase in LSE:VRCI on 28 September comes after a series of developments that have strengthened the company's product and commercialisation pipeline.

The most recent major development was the announcement that Verici plans to launch TranscripTx in Q4 2026.

TranscripTx is designed to identify genetic variations relevant to transplant patients. The test uses next-generation sequencing and Verici's AI-enabled approach to select genes associated with biological processes relevant to transplantation.

The timing is important because the company is moving from a relatively concentrated diagnostic portfolio toward a broader platform of tests and services.

The share-price move should therefore be viewed in the context of increasing product activity, although a single day's percentage gain does not establish that one particular announcement caused the entire move.

What Is TranscripTx and Why Is It Important?

TranscripTx is one of Verici Dx's most important upcoming commercial products.

The genetic test is designed specifically for the transplant community and identifies genetic variants that may influence how patients respond to therapies or their longer-term risk of graft failure.

The test uses sequencing of peripheral-blood RNA and incorporates an AI-enabled gene-selection process.

Verici expects the test to be offered as a laboratory-developed test through its CLIA-certified and CAP-accredited laboratory.

The company also sees TranscripTx as a way to generate additional commercial value from its existing clinical data and biological-sample repository.

For investors, the significance extends beyond the individual test because successful commercialisation could demonstrate that Verici can use its existing data and scientific infrastructure to develop additional diagnostic products.

Why Is Tutivia Important for LSE:VRCI?

Tutivia remains a core part of Verici Dx's commercial strategy.

The test is designed for patients following kidney transplantation and aims to detect acute rejection earlier, potentially providing clinicians with additional information when managing transplant recipients.

During the first quarter of 2026, Verici reported 392 Tutivia tests, representing a 32% increase from the previous quarter and a 34% increase year over year.

Seven new transplant centres ordered the test during the quarter, while one additional centre incorporated Tutivia into its clinical protocols.

Repeat ordering also increased, with several existing centres recording significant growth in testing volumes.

This is important because repeat utilisation can provide a clearer indication of commercial adoption than one-off orders.

What Does US Expansion Mean for Verici Dx?

US market access has become another important catalyst for LSE:VRCI.

Verici completed its clinical laboratory authorisation across all 50 US states and Washington, D.C. after receiving certification from New York State.

New York is particularly relevant because it has a substantial kidney-transplant population and represents an important market for transplant diagnostics.

Nationwide laboratory access removes one geographical barrier to commercial expansion and potentially allows Verici to work with a broader network of transplant centres.

The key issue now is converting that regulatory and laboratory access into actual testing volumes and recurring commercial demand.

Why Is the Olink Partnership Relevant?

Verici Dx also announced that it had become an Olink Certified Service Provider.

The arrangement expands the company's ability to offer advanced proteomics services through its accredited laboratory.

Proteomics can complement RNA-based diagnostics by providing information about proteins and biological pathways involved in disease and treatment response.

For Verici, the opportunity is broader than providing testing services to external customers. The company can also use proteomics capabilities to support biomarker discovery, algorithm development and validation of future diagnostic products.

This could potentially strengthen its wider multiomic platform.

What Is the Potential of Verici Dx's PTRA Test?

Another important part of the company's pipeline is the Pre-Transplant Risk Assessment, or PTRA, test.

A recent health-economic analysis estimated that widespread use of PTRA across the US standard-risk kidney-transplant population could potentially generate more than $191 million in healthcare savings over two years.

The test is designed to assess the risk of early acute rejection before transplantation.

The underlying concept is to help clinicians differentiate patients who may require more intensive immunosuppression from those who could potentially avoid unnecessary treatment exposure.

The economic analysis provides additional commercial evidence around the potential value of precision diagnostics, although the estimated healthcare savings should not be interpreted as guaranteed revenue for Verici Dx.

What Are Investors Watching Next for LSE:VRCI?

The most immediate catalyst is the planned Q4 2026 launch of TranscripTx.

Investors will be watching the timing of the launch, initial customer adoption and the commercial response from transplant centres and research organisations.

Tutivia testing volumes will also remain important. Continued sequential growth would provide evidence that the existing product is gaining traction.

Another focus will be the company's ability to convert nationwide US laboratory access into higher testing activity.

Investors are also likely to watch additional developments around PTRA, proteomics services and new diagnostic applications based on Verici's clinical data.

What Are the Main Risks for Verici Dx?

Verici remains a small healthcare diagnostics company, meaning commercial execution is particularly important.

The company needs to increase testing volumes, expand customer adoption and develop sustainable revenue streams while continuing to invest in research, laboratory infrastructure and product development.

Competition within transplant diagnostics is another consideration.

There is also a distinction between obtaining regulatory or laboratory access and achieving widespread clinical adoption. Nationwide availability creates an opportunity, but actual utilisation depends on clinicians, transplant centres, reimbursement arrangements and evidence supporting clinical value.

The company's future share-price performance can therefore remain sensitive to commercial milestones and funding requirements.

What Could Drive the Next LSE:VRCI Move?

The next significant catalyst is likely to be the TranscripTx Q4 launch.

Further growth in Tutivia testing volumes could provide another positive commercial signal, particularly if new transplant centres continue adopting the test and existing customers increase usage.

Expansion of Verici's multiomic laboratory services could also create additional revenue opportunities.

For LSE:VRCI, investors are now watching whether the company's scientific platform can translate into increasing commercial adoption across the US transplant market.

The 11.11% gain on 28 September 2026 therefore comes at an important point in Verici Dx's development, with the company entering a period where product launches, test volumes and commercial traction are becoming increasingly important alongside scientific progress.